NET ASSET VALUE – 31 December 2024

MARKN.

On the 31 December 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,198 million and NAV per share was SEK 53.77.



Allocation of NAV
Share of portfolio companyFair value (MSEK)Part of NAV per share (SEK)Share of NAV
Product Development    
Prokarium42%4866.2311.6%
Xspray Pharma18%2663.406.3%
KAHR Medical31%2082.664.9%
Empros Pharma79%2042.624.9%
Atrogi37%1762.254.2%
Lipum57%1411.803.4%
Microbiotica10%1381.773.3%
Xintela61%1311.683.1%
Geneos Therapeutics12%1061.352.5%
Toleranzia66%1031.322.4%
Mendus24%941.202.2%
AnaCardio17%690.891.7%
EpiEndo Pharmaceuticals9%570.731.4%
Synerkine Pharma43%530.681.3%
Egetis Therapeutics2%430.551.0%
Buzzard Pharmaceuticals14%290.370.7%
Sixera Pharma24%270.350.6%
Vitara Biomedical8%260.330.6%
Alder Therapeutics21%170.220.4%
Amarna Therapeutics58%120.150.3%
Strike Pharma16%90.110.2%
Total 2,39430.6657.0%





Commercial Growth    
NorthX Biologics92%1892.424.5%
Symcel31%1742.234.1%
Provell Pharmaceuticals72%781.001.9%
Chromafora31%730.931.7%
Nanologica43%700.891.7%
A3P Biomedical8%460.591.1%
Frontier Biosolutions2%190.240.5%
Bohus Biotech45%170.210.4%
Total 6658.5215.8%





Limited Partnerships, total 911.162.2%
     
Assets related to Portfolio companies 1932.474.6%
Other assets and liabilities 85510.9620.4%
     
Net asset value 4,19853.77100.0%
  

 

    

* indirect shares in Provell Pharmaceuticals

Datum 2025-01-09, kl 08:00
Källa MFN
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet